AFFIRM: study design Multicenter, randomized study N = 4060 patients
{"Image DocumentName": "AFFIRM: study design Multicenter, randomized study N = 4060 patients", "Image ImageDescription": "Mean follow-up: 3.5 years (max 6 years) Both treatment groups received oral anticoagulant therapy (INR 2.0 to 3.0): mandatory for rate control strategy, but only recommended for rhythm control strategy. RHYTHM CONTROL. AAD as chosen by physician: amiodarone, disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, dofetilide, or a combination. Cardioversion included as necessary. RATE CONTROL. Beta-blockers, calcium-channel blockers (verapamil and diltiazem), digoxin, or a combination. Treatment goal: Heart rate within range bpm during six-minute walk test. The AFFIRM Investigators. N Eng J Med 2002;347(23):", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}